Table 2. Univariate analysis of clinical variables for progression-free survival.

Variable	HR (95% CI)	P value
Age	1.02 (0.99-1.04)	0.18
Disease-free interval (≥24 vs < 24 months)	0.49 (0.27-0.89)	0.02
Estrogen-receptor (positive vs negative)	0.42 (0.21-0.83)	0.02
Progesterone-receptor (positive vs negative)	0.58 (0.32-1.03)	0.07
Adjuvant chemotherapy (yes vs no)	0.69 (0.37-1.27)	0.25
Prior anthracyclines and taxanes (yes vs no)	1.17 (0.63-2.17)	0.62
Prior lines for metastatic disease (≥ 1 vs 0)	1.64 (0.93-2.87)	0.09
Metastatic location (< 3 locations and no liver involvement vs ≥ 3 or hepatic)	2.92 (1.61-5.32)	0.0003
Hormonal therapy*	0.48 (0.2-1.17)	0.11

^*Only in subgroup of patients with bevacizumab continuation treatment and ER positive